Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Jan Aushadhi Diwas celebrations to generate awareness about the usages of generic medicines and benefits of Jan Aushadhi Pariyojana
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
This order is subject to initial advance payment as per the agreed terms of the contract
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure.
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated